Zobrazeno 1 - 10
of 109
pro vyhledávání: '"Karen Howarth"'
Autor:
Brendan Knapp, Laura Mezquita, Siddhartha Devarakonda, Mihaela Aldea, Saiama N. Waqar, Kym Pepin, Jeffrey P. Ward, Angela Botticella, Karen Howarth, Charlene Knape, Clive Morris, Ramaswamy Govindan, Benjamin Besse, Daniel Morgensztern
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
IntroductionCirculating tumor DNA (ctDNA) testing may identify patients at high risk for recurrence following chemoradiation (CRT) for locally advanced non-small cell lung cancer (LA-NSCLC). We evaluated the feasibility of ctDNA testing on a readily
Externí odkaz:
https://doaj.org/article/bdec53ddcf914269b586e80415fd720d
Autor:
Jordi Remon, Aurelie Swalduz, David Planchard, Sandra Ortiz-Cuaran, Laura Mezquita, Ludovic Lacroix, Cecile Jovelet, Etienne Rouleau, Camille Leonce, Frank De Kievit, Clive Morris, Greg Jones, Kelly Mercier, Karen Howarth, Emma Green, Maurice Pérol, Pierre Saintigny, Benjamin Besse
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234302 (2020)
Circulating tumor DNA (ctDNA)-based molecular profiling is rapidly gaining traction in clinical practice of advanced cancer patients with multi-gene next-generation sequencing (NGS) panels. However, clinical outcomes remain poorly described and deser
Externí odkaz:
https://doaj.org/article/93ae8d067940452fb391568395e4fc0e
Autor:
Marla Lipsyc-Sharf, Elza C. de Bruin, Katheryn Santos, Robert McEwen, Daniel Stetson, Ashka Patel, Gregory J. Kirkner, Melissa E. Hughes, Sara M. Tolaney, Ann H. Partridge, Ian E. Krop, Charlene Knape, Ute Feger, Giovanni Marsico, Karen Howarth, Eric P. Winer, Nancy U. Lin, Heather A. Parsons
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 40(22)
PURPOSE To examine the prevalence and dynamics of circulating tumor DNA (ctDNA) and its association with metastatic recurrence in patients with high-risk early-stage hormone receptor–positive breast cancer (HR+ BC) more than 5 years from diagnosis.
Autor:
David Planchard, Pierre Saintigny, Jean-Yves Blay, Benjamin Besse, Maurice Perol, Jean-François Guichou, Sylvie Chabaud, Luc Friboulet, Emma Green, Clive Morris, Karen Howarth, Frank de Kievit, Natalie Hoog-Labouret, Celine Mahier-Aït Oukhatar, Caroline Caramella, Etienne Giroux Leprieur, Isabelle Monnet, Etienne Brain, Radj Gervais, Christine Raynaud, Claire Tissot, Maud Ngo-Camus, Virginie Westeel, Yohann Loriot, Ludovic Lacroix, Washington R. Chumbi Flores, Virginie Avrillon, Anne Pradines, Cecile Jovelet, Camille Leonce, Julien Mazieres, Mihalea Aldea, Aurélie Swalduz, Laura Mezquita, Sandra Ortiz-Cuaran
Purpose:The limited knowledge on the molecular profile of patients with BRAF-mutant non–small cell lung cancer (NSCLC) who progress under BRAF-targeted therapies (BRAF-TT) has hampered the development of subsequent therapeutic strategies for these
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ac9163cfbba9d2de50090974b699f2
https://doi.org/10.1158/1078-0432.c.6530096
https://doi.org/10.1158/1078-0432.c.6530096
Autor:
Luc Friboulet, Benjamin Besse, Jean-Charles Soria, Ken A. Olaussen, Christophe Massard, Fabrice Andre, Alexander M. Eggermont, Eric Angevin, Eric Solary, Lambros Tselikas, Thierry De Baere, Nathalie Auger, Catherine Richon, Ludovic Lacroix, Stefan Michiels, Maud Ngo-Camus, Claudio Nicotra, Antoine Hollebecque, Rastilav Bahleda, Gilles Vassal, Aurélie Abou Lovergne, Linda Mahjoubi, Pernelle Lavaud, Charles Naltet, Floriane Braye, Pauline Tesson, Justine Galissant, Dariia Samofalova, Olivier Deas, Karen Howarth, Tony Sourisseau, Jean-Yves Scoazec, Jean Paul Thiery, Rosa L. Frias, Ahsan Z. Rizvi, Ludovic Bigot, Anas Gazzah, David Planchard, Francesco Facchinetti, Laura Mezquita, Gonzalo Recondo
Supplementary Figure 3: NF2 deleterious mutations and sensitivity to lorlatinib (corresponding to main Figure 4).
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::295ddc322c4e352d2e365e9861f1b33b
https://doi.org/10.1158/1078-0432.22474059
https://doi.org/10.1158/1078-0432.22474059
Autor:
Luc Friboulet, Benjamin Besse, Jean-Charles Soria, Ken A. Olaussen, Christophe Massard, Fabrice Andre, Alexander M. Eggermont, Eric Angevin, Eric Solary, Lambros Tselikas, Thierry De Baere, Nathalie Auger, Catherine Richon, Ludovic Lacroix, Stefan Michiels, Maud Ngo-Camus, Claudio Nicotra, Antoine Hollebecque, Rastilav Bahleda, Gilles Vassal, Aurélie Abou Lovergne, Linda Mahjoubi, Pernelle Lavaud, Charles Naltet, Floriane Braye, Pauline Tesson, Justine Galissant, Dariia Samofalova, Olivier Deas, Karen Howarth, Tony Sourisseau, Jean-Yves Scoazec, Jean Paul Thiery, Rosa L. Frias, Ahsan Z. Rizvi, Ludovic Bigot, Anas Gazzah, David Planchard, Francesco Facchinetti, Laura Mezquita, Gonzalo Recondo
Purpose:Lorlatinib is a third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor with proven efficacy in patients with ALK-rearranged lung cancer previously treated with first- and second-generation ALK inhibitors. Beside compound
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::497a587b9ae25004327b21a79ff50bad
https://doi.org/10.1158/1078-0432.c.6528672
https://doi.org/10.1158/1078-0432.c.6528672
Autor:
Luc Friboulet, Benjamin Besse, Jean-Charles Soria, Ken A. Olaussen, Christophe Massard, Fabrice Andre, Alexander M. Eggermont, Eric Angevin, Eric Solary, Lambros Tselikas, Thierry De Baere, Nathalie Auger, Catherine Richon, Ludovic Lacroix, Stefan Michiels, Maud Ngo-Camus, Claudio Nicotra, Antoine Hollebecque, Rastilav Bahleda, Gilles Vassal, Aurélie Abou Lovergne, Linda Mahjoubi, Pernelle Lavaud, Charles Naltet, Floriane Braye, Pauline Tesson, Justine Galissant, Dariia Samofalova, Olivier Deas, Karen Howarth, Tony Sourisseau, Jean-Yves Scoazec, Jean Paul Thiery, Rosa L. Frias, Ahsan Z. Rizvi, Ludovic Bigot, Anas Gazzah, David Planchard, Francesco Facchinetti, Laura Mezquita, Gonzalo Recondo
Supplementary figures legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf2d32d7f78b8b3bf5bb97fa77f464e1
https://doi.org/10.1158/1078-0432.22474053
https://doi.org/10.1158/1078-0432.22474053
Autor:
Susanne Flach, Karen Howarth, Sophie Hackinger, Christodoulos Pipinikas, Pete Ellis, Kirsten McLay, Giovanni Marsico, Tim Forshew, Christoph Walz, Christoph A. Reichel, Olivier Gires, Martin Canis, Philipp Baumeister
Publikováno v:
Br. J. Cancer 126, 1186–1195 (2022)
Background Head and neck squamous cell carcinoma (HNSCC) remain a substantial burden to global health. Cell-free circulating tumour DNA (ctDNA) is an emerging biomarker but has not been studied sufficiently in HNSCC. Methods We conducted a single-cen
Autor:
Maria Coakley, Prithika Sritharan, Guillermo Villacampa, Claire Swift, Kathryn Dunne, Lucy Kilburn, Katie Goddard, Patricia Rojas, Andy Joad, Warren Emmett, Charlene Knape, Karen Howarth, Peter S. Hall, Catherine Harper-Wynne, Tamas Hickish, Iain Macpherson, Alicia F. Okines, Andrew M. Wardley, Duncan Wheatley, Simon Waters, Rosalind Cutts, Isaac Garcia-Murillas, Judith Bliss, Nicholas Turner
Publikováno v:
Cancer Research. 83:PD5-03
Background: Detection of circulating tumour DNA (ctDNA) in patients (pts) who have completed treatment for early-stage breast cancer is associated with a high risk of future relapse. Identifying those at high risk of subsequent relapse may allow tail
Autor:
Mitchell J. Elliott, Zachary Veitch, Philippe Bedard, Eitan Amir, Aaron Dou, Jesus Fuentes Antras, Michelle Nadler, Nicholas Meti, Nancy Gregorio, Elizabeth Shah, Helen Chow, Nathan Campbell, Samantha Terrell, Charlene Knape, Karen Howarth, Lillian Siu, Hal Berman, David W. Cescon
Publikováno v:
Cancer Research. 83:P6-01
Background: ctDNA dynamics are associated with treatment response, and ctDNA detection following treatment is associated with disease recurrence in early breast cancer (EBC). Highly sensitive assays may permit effective risk stratification and guide